Cutaneous lymphomas other than mycosis fungoides in Singapore: a clinicopathological analysis using recent classification systems

Abstract

The predominance of cutaneous T-cell lymphomas in this case series closely matched that reported from east Asia; cutaneous B-cell lymphomas are much less common than in Europe. The EORTC classification, which is designed only for primary cutaneous lymphomas, should be used in conjunction with the WHO classification because of the high prevalence of cutaneous lymphomas as the secondary site of disease from systemic lymphoma. In addition, subcutaneous panniculitis-like T-cell lymphoma is a primary cutaneous lymphoma where systemic involvement is common at initial presentation. We propose full immunophenotyping and complete clinical evaluation with staging investigations for all patients presenting with cutaneous lymphomas other than MF.

Aggressive subcutaneous panniculitis-like T-cell lymphoma with hemophagocytosis in two children (subcutaneous panniculitis-like T-cell lymphoma)

“…In a series of 6 adult patients with SPTCL in Singapore, 5 patients developed systemic involvement with an aggressive disease course, requiring the use of multiagent chemotherapy, with a median survival of 7 months from presentation. 26 Although this series was reported before the proposed distinction of SPTCL into a/b or g/d T-cell phenotype, patients with SPTCL in our region may differ from those reported in the Western literature, with regard to the severity and aggressiveness of the condition.…”

“…1,4,5,7,10,12,24,[26][27][28][29][30][31][32] There are only two previous reports of patients who responded to fludarabinebased chemotherapy. 33,34 There are a few reports of patients who received low-dose systemic chemotherapy, eg, cyclophosphamide, methotrexate, and chlorambucil.…”

“…33,34 There are a few reports of patients who received low-dose systemic chemotherapy, eg, cyclophosphamide, methotrexate, and chlorambucil. 5,7,26 Recent reports have suggested the use of systemic corticosteroids for control of symptoms. 1,10,12,24,35 However, most responses were relatively short lived, with subsequent progression once steroids were tapered.…”

Cutaneous Manifestations in Non-Hodgkin’s Lymphoma

“…[7][8][9][10][11][12] The reported incidence of primary and secondary cutaneous lesions is equally common in both T-and B-cell lymphomas. 1 Their average frequency is 0.3 of 100,000, with 65% T-NHL, 25% B-NHL and 10% true HL or rare cell types. 4,13 The frequency of secondary skin involvement in NHL is 16.2% in the present study, which is very close to the reported incidence of 17%.…”

“…1 Skin lesions can be seen in Hodgkin's 2,3 and non-Hodgkin's lymphomas (NHL). [4][5][6][7][8][9][10][11][12] The secondary involvement of skin in lymphoma is rare and is associated with advanced stage and poor prognosis.…”